BioVaxys Technology Corp.
BVAXF · OTC
10/31/2024 | 10/31/2023 | 10/31/2022 | 10/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $0 | $0 | $1 | $1 |
| G&A Expenses | $2 | $2 | $3 | $4 |
| SG&A Expenses | $3 | $2 | $3 | $5 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $2 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $3 | $2 | $4 | $6 |
| Operating Income | -$3 | -$2 | -$4 | -$6 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$1 | -$5 | -$8 | -$0 |
| Pre-Tax Income | -$4 | -$8 | -$12 | -$6 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$4 | -$8 | -$12 | -$6 |
| % Margin | – | – | – | – |
| EPS | -0.202 | -0.573 | -1.2 | -0.779 |
| % Growth | 64.7% | 52.3% | -54% | – |
| EPS Diluted | -0.202 | -0.573 | -1.2 | -0.779 |
| Weighted Avg Shares Out | 20 | 13 | 10 | 8 |
| Weighted Avg Shares Out Dil | 20 | 13 | 10 | 8 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $3 | $2 | $4 | -$0 |
| EBITDA | $0 | $0 | $0 | -$6 |
| % Margin | – | – | – | – |